PREP

What can we help you find?
[[thumbnail_alt_text]]
Results were announced at the virtual 23rd International AIDS Conference.
[[thumbnail_alt_text]]
In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.
[[thumbnail_alt_text]]
PrEP-AP is intended to lower out-of-pocket costs for both uninsured and insured people who are eligible for PrEP services such as laboratory tests.
[[thumbnail_alt_text]]
When taken daily, PrEP is highly effective for preventing HIV from sex or injection drug use.
[[thumbnail_alt_text]]
New research indicates that even with effective antiretroviral treatment, HIV may still affect the central nervous system.
 
[[thumbnail_alt_text]]
Remdesivir, the investigational drug for the treatment of the coronavirus disease 2019 (COVID-19), will be sold for $390 per vial.
[[thumbnail_alt_text]]
Although researchers know that HIV enters the brain within 8 days of infection, less is known about whether HIV-infected brain cells can release the virus, letting it migrate from the brain back into the body to infect other tissues.  
 
[[thumbnail_alt_text]]
Access and adherence to pre-exposure prophylaxis is vital in eradicating the HIV epidemic in the United States.
[[thumbnail_alt_text]]
Closing these gaps in care could improve access for those worse affected by HIV in developing countries.
[[thumbnail_alt_text]]
HIV drug prices rose 34% between 2012 and 2018 and continue to climb, which experts say is a huge issue.
[[thumbnail_alt_text]]
Uptake of PrEP has been slow, particularly among at-risk individuals between 13-19 years of age ar risk for HIV infection.
[[thumbnail_alt_text]]
Pharmacy Times® interviewed James Krellenstein, co-Founder, PrEP4All Collaboration and Organizer, The COVID-19 Working Group, to discuss the development of PrEP for the COVID-19 pandemic.